A high degree of consolidation is the defining feature of the competitive landscape of the global biotherapeutics cell line development market, finds Transparency Market Research. Becton Dickinson and Co. and Beckman Coulter, the top two companies operating in the biotherapeutics cell line development market, accounted for 85% of the overall market in 2015.
This consolidation has led to reduced market shares for other players and has also abated the possibility of new entrants, thereby offering prominent opportunities for business expansion existing leaders. Over the coming years, these players will need to focus on advancements in technologies to gain a competitive edge over each other.
Unmet Medical Needs in Emerging Economies to Present Lucrative Opportunities for Biotherapeutics Cell Line Development
The increasing prevalence of chronic diseases, stimulated by the rapid growth of the global geriatric population, has created favorable conditions for the progression of biotherapeutics. Currently, the increasing percentage of elderly individuals in the world’s population is a significant trend, which is likely to intensify over the years to come. This rise in geriatric population is impelling the incidence of chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis. Biotherapeutics, supported by its high efficiency, is grabbing substantial attention from patients as well as medical professionals for the treatment of these diseases, leading to a significant thrust to the development of biotherapeutics cell line across the world.
Looking forward, emerging economies in Asia Pacific, Latin America, and Africa, laden with unmet medical needs, will provide lucrative opportunities for biotherapeutics cell line development over the next few years. Apart from this, the growing demand for monoclonal antibodies is also projected to stimulate development activities for these cell lines in the near future.
Stringent Regulations Could Delay Product Development, Hamper Market Growth
Although the market for biotherapeutics cell line development looks thriving at present, the stringent norms and policies that regulate cell culture procedures in the production of biotherapeutics create severe issues for market participants.
As the development of stable cell line producing biologics needs to follow standard operating procedures and compliance, and requires to monitor product quality by performing tests in line with SOPs and regulations, existing players face delay in product development. These regulations also restrict the entry of new players in this market.
Single Cell Cloning to Remain Most Preferred Process for Cell Line Development
The global market for biotherapeutics cell line development is estimated to expand at a steady CAGR of 7.50% during the period from 2015 to 2022, with the opportunity rising from US$56.03 mn in 2014 to US$99.8 mn by the end of the forecast period.
North America has been leading this market since the last few years and is projected to remain the key revenue contributor in the near future. The region is likely to witness a rise in its market opportunity from US$23.5 mn in 2014 to US$41 mn by 2022. However, Asia Pacific is anticipated to report the fastest CAGR of 9.40% during the forecast period.
Single cell cloning was the main cell line development process followed in 2014. Analysts expect it to continue to lead with a majority share throughout the forecast period. Outsourcing will emerge as the most preferred cell line development option for biotherapeutics over the forthcoming years, states TMR.
The information presented in this review is based on the findings of a report by Transparency Market Research titled “Biotherapeutics Cell Line Development Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2022.”
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453